Pharmalink Raises SEK96 Million to Undertake Pivotal Studies with Lead Programs in Cancer Therapy and Renal Disease

23:06 EDT 3 Oct 2013 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
STOCKHOLM, October 4, 2013 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces it has raised SEK96 million (€11m / US$15m) in a Series C financing round. The round was co-led by two of the ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Pharmalink Raises SEK96 Million to Undertake Pivotal Studies with Lead Programs in Cancer Therapy and Renal Disease"

Search BioPortfolio:
Advertisement

Relevant Topic

Transplantation
Latest News Clinical Trials Research Drugs Reports Corporate
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Advertisement

Searches Linking to this Story